Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
Centogene N.V. (symbol: CNTG) is a leading global company in the field of genetic diagnostic testing for rare hereditary diseases. With an expansive test portfolio covering over 2,800 genes, as well as biochemical and biomarker tests, the company offers unparalleled expertise in whole exome sequencing and whole genome sequencing. Centogene's mission is to provide data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by diagnosing the root causes of symptoms early on.
Centogene leverages its unique CentoMD® mutation database, integrating genetic and clinical information to deliver the highest quality genetic testing and biomarker development. This extensive database allows the company to maintain the largest systematic documentation of genetic results worldwide.
Beyond individual diagnostic services, Centogene is a pivotal partner for pharmaceutical companies, offering essential services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. The company operates in two main segments: pharmaceutical and diagnostics, serving regions including Europe, the Middle East, North America, and Latin America.
Recent achievements include the launch of innovative genomic and multiomic products, a significant joint venture in Saudi Arabia, and expanded collaborations with long-standing and new pharma partners. Despite the challenges posed by current financial markets, Centogene remains committed to growth and profitability, exploring strategic alternatives to unlock value for its stakeholders.
With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, Centogene's research and development efforts have led to over 285 peer-reviewed publications. The company's pioneering work in rare and neurodegenerative diseases has fostered collaborations with over 50 pharmaceutical partners, accelerating drug discovery and development.
To discover more about Centogene's products, pipeline, and patient-driven purpose, visit their website and follow them on LinkedIn.
Centogene and Alnylam Pharmaceuticals have launched a joint program named TRAMmoniTTR to conduct genetic screening for hereditary Transthyretin-related Amyloidosis (ATTRv). This initiative builds on the previous TRAM Study, which identified over 1% of 5,000 participants with ATTRv. The TRAMmoniTTR Study will monitor symptomatic and asymptomatic TTR-positive individuals for two years, using Centogene's biomarker profiling to enhance diagnostics. Experts from both companies emphasize the importance of early diagnosis and personalized treatment approaches.
Centogene N.V. (CNTG) has expanded its partnership with PTC Therapeutics to enhance genetic testing for Aromatic L-amino Acid Decarboxylase (AADC) deficiency across Europe, the Middle East, and Latin America. This initiative will provide free biochemical and genetic testing to patients enrolled in the REVEAL CP study, aimed at identifying AADC deficiency in individuals with cerebral palsy. The study utilizes CentoCard® blood samples to detect elevated 3-O-Methyldopa levels, critical for timely diagnosis and treatment options for this ultra-rare genetic disorder.
On November 13, 2020, CENTOGENE (Nasdaq: CNTG) announced the nomination of Dr. Jonathan G. Sheldon to the Supervisory Board, to be proposed at an Extraordinary General Meeting. Dr. Sheldon, Senior VP at QIAGEN, is recognized for his contributions to data interpretation in rare diseases. CENTOGENE focuses on transforming clinical and genetic data to assist in diagnosis and drug development for rare diseases, boasting a repository of over 3.6 billion data points from 570,000 patients across 120 countries.
Centogene (Nasdaq: CNTG) has partnered with Fujirebio Europe to enhance COVID-19 antigen testing using the LUMIPULSE® G technology, specifically in German airports. Fujirebio will supply LUMIPULSE G1200 instruments, enabling rapid results within 40 minutes from sample receipt. Centogene will manage sample collection via swabs and conduct analysis in their laboratories. The initial testing phase with Lufthansa starts November 12, offering free tests for select flights from Hamburg. This collaboration aims to improve COVID-19 testing capabilities and contribute to prevention efforts.
CENTOGENE has expanded its SARS-CoV-2 testing services to Berlin Brandenburg Airport (BER), marking its fourth major airport testing center in Germany. Passengers at BER, alongside the general public, can now access PCR tests from 7:00 a.m. to 7:00 p.m. without prior appointments. The initiative aims to facilitate safe travel during the COVID-19 pandemic, with results provided within 24 hours. CENTOGENE's test has received Emergency Use Authorization from the FDA, ensuring reliability and compliance with data privacy regulations.
Centogene N.V. (Nasdaq: CNTG) announces the departure of Prof. Arndt Rolfs as CEO effective October 20, 2020, with Dr. Andrin Oswald to take over on December 1, 2020. Prof. Rolfs will continue to advise during the transition. Dr. Oswald brings over 20 years of healthcare leadership experience, aiming to further expand Centogene's role in rare disease diagnostics. The company has developed a unique platform based on extensive real-world data, supporting improved clinical outcomes and drug development for rare diseases. Prof. Rolfs' leadership was instrumental in positioning the company for growth.
Centogene N.V. (Nasdaq: CNTG) has increased its full-year 2020 revenue guidance, projecting revenues above €80 million, up from a previous range of €60-65 million. This adjustment follows improved performance in their Covid-testing segment and a recovery in core business operations post-Q2 pandemic impacts. CFO Richard Stoffelen noted substantial growth in Covid-testing revenue and expressed optimism about continued business momentum. The company monitors its outlook closely as it aims to support health and safety globally.
Centogene N.V. (Nasdaq: CNTG) announced that the FDA has granted Emergency Use Authorization (EUA) for its new SARS-CoV-2 RT-PCR test, CentoSure. This test allows for screening individuals without COVID-19 symptoms, aiming to enhance widespread testing efforts in the U.S. and beyond. Prof. Arndt Rolfs, CEO, emphasized the importance of broad testing to curb virus spread. The assay has passed validation in their certified lab, indicating a commitment to quality and precision in COVID-19 diagnostics.
Centogene (Nasdaq: CNTG) has partnered with U-Diagnostics to enhance COVID-19 testing in the Netherlands amidst rising infection rates. This collaboration aims to address the current testing capacity shortage by leveraging Centogene's testing technologies, including the CentoSwab™ and RT-PCR analysis, to provide timely testing services. The partnership underscores the importance of innovative solutions to combat the pandemic. Both companies aim to facilitate accessible testing to protect community health and support economic stability.
Centogene N.V. (Nasdaq: CNTG) has been awarded the ISO/IEC 27001:2017 certification, affirming its adherence to international standards for Information Security Management Systems. This recognition reflects the company's commitment to safeguarding patient, employee, and business partner data. The certification follows an extensive audit, confirming that Centogene's IT systems uphold the highest levels of confidentiality, availability, and integrity. Key executives emphasized the significance of this milestone in enhancing secure data processes in biotech.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
What does Centogene N.V. specialize in?
What is CentoMD®?
Which segments does Centogene operate in?
What regions does Centogene serve?
Who are Centogene’s main partners?
What are some recent achievements of Centogene?
How does Centogene contribute to drug discovery?
What research certifications does Centogene hold?
How extensive is Centogene's physician network?
Where can I learn more about Centogene?
